ADVERTISEMENT
Search

Transitions Magazine

Transitions is published bi-monthly for members of the APhA New Practitioner Network. The online newsletter contains information focused on life inside and outside pharmacy practice, providing guidance on various areas of professional, personal, and practice development. Each issue includes in-depth articles on such topics as personal financial management, innovative practice sites, career profiles, career development tools, residency and postgraduate programs, and more.

Natalie Fritzson
/ Categories: APhA News

DEA extends telemedicine flexibilities through 2025

On November 15, DEA announced the extension of current telemedicine flexibilities for prescription-controlled medications through the end of 2025. This includes substances such as buprenorphine and Adderall.

During the COVID-19 pandemic, DEA issued temporary rules that allow providers to prescribe these substances without first meeting a patient in person. Those rules were set to expire at the end of 2024 but have now been extended for 1 more year—until the end of 2025.

Last year, DEA received tens of thousands of comments and held 2 days of public listening sessions in response to a set of proposed telemedicine rules. Given that feedback and discussion, the agency made its decision. The full text of the "Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications" is posted in the Federal Register.

Print
941 Rate this article:
No rating
Please login or register to post comments.
Advertisement
Advertisement
Advertisement
Advertisement

ADVERTISEMENT